Respiratory-related medical expenditure and inpatient utilisation among COPD patients receiving long-acting bronchodilator therapy

Journal of Medical Economics

Volumn 14, Issue 2, 2011, Pages 147-158

  Cao, Zhun ^a   Zou, Kelly H ^b   Baker, Christine L ^b   Su, Jun ^c   Paulose Ram, Ryne ^b   Durden, Emily ^a   Shi, Nianwen ^a   Shah, Hemal ^c  

^a THOMSON REUTERS   (United States)

^b PFIZER INC   (United States)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

Claims data; COPD; Costs; Long acting bronchodilator therapy; Utilisation

Indexed keywords

BRONCHODILATING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL FUMARATE; LONG ACTING DRUG; OXYGEN; RESPIRATORY STIMULANT AGENT; SALMETEROL; SHORT ACTING DRUG; TIOTROPIUM BROMIDE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EVALUATION; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DEMOGRAPHY; DRUG COST; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HOSPITAL ADMISSION; HOSPITAL PATIENT; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OXYGEN THERAPY; RURAL POPULATION; URBAN POPULATION;

ADULT; AGED; BRONCHODILATOR AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEALTH RESOURCES; HOSPITAL COSTS; HUMANS; INPATIENTS; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; SCOPOLAMINE DERIVATIVES; TIME FACTORS; UNITED STATES;

EID: 79953016195     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696998.2011.552582     Document Type: Article

References (30)

1. Rennard SI. COPD: overview of definitions, epidemiology and factors influenc-ing its development. Chest 1998;113(4 Suppl): 235-241S
2. American Lung Association, Trends in COPD (Chronic Bronchitis and Emphysema): Morbidity and Mortality, February 2010. Available at: http://www.lungusa.org/finding-cures/our-research/epidemiology-and-statistics- rpts.html http://www.lungusa.org/finding-cures/our-research/epidemiol-ogy-and- statistics-rpts.html. Accessed July 26, 2010
3. Miller JD, Foster T, Boulanger L, et al. Direct cost of COPD in the U.S.: an analysis of medical expenditure panel survey (MEPS) data. COPD 2005; 3:311-318 (Pubitemid 43879447)
4. Halpern MT, Stanford RH, Borker R. The burden of COPD in the U.SA: Results of the confronting COPD survey. Respir Med 2003;97(Suppl C):S81-89 (Pubitemid 36266873)
5. Cannon HE. Assessing the need for a clinical COPD care program in a man-aged care organization. J Manag Care Pharm 2004;10(4 Suppl):S17-21
6. Mapel DW, Hurley JS, Frost FJ, et al. Health care utilization in chronic obstruc-tive pulmonary disease: a case-control study in a health maintenance orga-nization. Arch Intern Med 2000;160:2653-2658
7. Hilleman DE, Dewan N, Malesker M, et al. Pharmacoeconomic evaluation of COPD. Chest 2000;118:1278-1285
8. Pauwels RA, Buist AS, Calverley PM, et al. GOLD ScientificCommittee. Global strategy for the diagnosis, management, and prevention of chronic obstruc-tive pulmonary disease. NHLBI/WHO global initiative for chronic obstructive lung disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001;163:1256-1276 (Pubitemid 32378468)
9. GOLD-the Global Initiative for Chronic Obstructive Lung Disease. Available at: http://www.goldcopd.com/http://www.goldcopd.com/Accessed August, 2009
10. Sin DD, McAlister FA, Man P, et al. Contemporary management of chronic obstructive pulmonary disease: Scientific review. JAMA 2003;290: 2301-2312 (Pubitemid 37430563)
11. Tashkin DP, Cooper CB. The role of long-acting bronchodilators in the man-agement of stable COPD. Chest 2004;125:249-259 (Pubitemid 38114590)
12. Vincken W, van Noord JA, Greefhorst AP, et al. Improved health outcomes in patients with COPD during 1 yea treatment with tiotropium. Eur Respir J 2002;19:209-216 (Pubitemid 34162819)
13. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. http://www.ncbi.nlm.nih.gov/pubmed/10208192?itool= EntrezSystem2.PEntrez.Pubmed.Pubmed-ResultsPanel. Pubmed- RVDocSum&ordinalpos=43 Chest 1999;115:957-965 (Pubitemid 29193661)
14. Aalbers R, Ayres J, Backer V, et al. Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Eur Respir J 2002;19:936-943 (Pubitemid 34567910)
15. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449-456 (Pubitemid 36173708)
16. Friedman M, Menjoge SS, Anton SF, et al. Healthcare costs with tiotropium plus usual care versus usual care alone following 1 year of treat-ment in patients with chronic obstructive pulmonary disorder (COPD). Pharmacoeconomics 2004;22:741-749 (Pubitemid 38998498)
17. Akazawa M, Hayflinger C, Stanford RH, et al. Economic assessment of initial maintenance therapy for chronic obstructive pulmonary disease. Am J Manag Care 2008;14:438-448 (Pubitemid 352031000)
18. Delea TE, Hagiwara M, Dalal AA, et al. Healthcare use and costs in patients with chronic bronchitis initiating maintenance therapy with fluticasone/sal-meterol vs other inhaled maintenance therapies. Curr Med Res Opin 2009;25:1-13
19. Chang S, Hansen LG. Health Research Data for the Real World The MarketScan® Databases. Thomson Reuters. July 2009. Web site http://thomsonreuters.com/products-services/healthcare/healthcare-products/ pharmaceuticals/epidemiolgy-res/mktscan-res-db Accessed January 16, 2010
20. The Kaiser Family Foundation, Examining Sources of Coverage Among Medicare Beneficiaries: Supplemental Insurance, Medicare Advantage, and Prescription Drug Coverage Findings from the Medicare Current Beneficiary Survey, 2006. Available at: http://www.kff.org/medicare/upload/7801.pdf http://www.kff.org/medicare/upload/7801.pdf Accessed July 26, 2010
21. Goetzel RZ, Hawkins K, Ozminkowski RJ, et al. The health and productivity cost burden of the "Top 10" physical and mental health conditions affecting six large U.S. employers in 1999. J Occup Environ Med 2003;45:5-14 (Pubitemid 36091516)
22. Crown WH, Finkelstein S, Berndt FR, et al. The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychol 2002;63:963-971 (Pubitemid 35388053)
23. Durden E, Ben Joseph R, Huse D, et al. The economic costs of obesity to self-insured employers. J Occup Environ Med 2008;50:991-997
24. Schulman K, Kehles J. Economic burden of metastatic bone disease in the U.S. Cancer 2007;109:2334-2342 (Pubitemid 46801565)
25. US Department of Labor Bureau of Labor Statistics Consumer Price Index. Available at: http://www.bls.gov/cpi/cpifact4.htm Accessed August 2009
26. Charlson ME, Pompei P, Ales KL, et al. Anew method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1997;40:373-383
27. D'Hoore W, Bouckaert A, Tilquin C Practical considerations on the use of the Charlson Comorbidity Index with administrative data bases. J Clin Epidemiol 1996;49:1429-1433 (Pubitemid 27028932)
28. Nelder JA, Wedderburn R. Generalized linear models. J R Stat Soc, Ser A (General) 1972;135:370-384
29. Najafzadeh M, Marra CA, Sadatsafavi M, et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax 2008;63:962-967
30. Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007;146:545-555 (Pubitemid 351650535)